20S-Protopanaxadiol Inhibits P-Glycoprotein in Multidrug Resistant Cancer Cells

Abstract

One of the major causes for cancer cells to resist current chemotherapy is attributed to the over-expression of P-glycoprotein (P‐gp), resulting in insufficient drug delivery to the tumor sites. Protopanaxadiol ginsenosides Rg3 and Rh2 are known to induce apoptosis and significantly enhance the tumor inhibitory effects of chemotherapeutics in a synergistic fashion. One of the possible mechanisms is by blocking P‐gp activity. The final deglycosylation metabolite of protopanaxadiols (PPDs) in vivo is 20(S)-protopapanaxadiol (aglycone PPD, aPPD), which has also shown anticancer activity and synergy with chemotherapy drugs. In the present study, P‐gp over-expressing cancer cells were utilized to test whether aPPD also inhibits P‐gp activity. We found that aPPD caused similar cytotoxicity in P388adr cells as their parental non-MDR cells, suggesting that aPPD may not be a substrate of P‐gp. On the other hand, the calcein AM efflux assay showed that aPPD was able to inhibit P‐gp activity as potently as verapamil on MDR cells. The blockage of P‐gp activity was highly reversible as wash-out of aPPD resulted in an immediate recovery of P‐gp activity. Unlike verapamil, aPPD did not affect ATPase activity of P‐gp suggesting a different mechanism of action. The above results indicate that aPPD, unlike its precursor ginsenosides Rg3 and Rh2, is not a substrate of P‐gp. It is also the first time that aPPD has showed a reversible nature of its P‐gp inhibition. In addition to its pro-apoptotic nature, aPPD may be a potential new P‐gp inhibitor for cancer treatment.

Key words

P‐glycoprotein - ginsenosides - MDR - protopanaxadiol

References

• 1 Dey S, Ramachandra M, Pastan I, Gottesman M M, Ambudkar S V. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.  Proc Natl Acad Sci USA. 1997;  94 10594-10599
• 2 Zhou S, Lim L Y, Chowbay B. Herbal modulation of P-glycoprotein.  Drug Metab Rev. 2004;  36 57-104
• 3 Perry M C. The chemotherapy source book, 2nd edition. Baltimore; Williams & Wilkins 1996: 1071
• 4 Barecki-Roach M, Wang E J, Johnson W W. Many P-glycoprotein substrates do not inhibit the transport process across cell membranes.  Xenobiotica. 2003;  33 131-140
• 5 Kemper E M, Boogerd W, Thuis I, Beijnen J H, van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?.  Cancer Treat Rev. 2004;  30 415-423
• 6 Leontieva O V, Preobrazhenskaya M N, Bernacki R J. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin 14-O-hemiadipate.  Invest New Drugs. 2002;  20 35-48
• 7 Varma M V, Ashokraj Y, Dey C S, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.  Pharmacol Res. 2003;  48 347-359
• 8 Di Pietro A, Dayan G, Conseil G, Steinfels E, Krell T, Trompier D, Baubichon-Cortay H, Jault J. P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.  Braz J Med Biol Res. 1999;  32 925-939
• 9 Bruce C. Anticancer drug development. San Diego, Calif., London; Academic 2002: 77-79
• 10 Radad K, Gille G, Moldzio R, Saito H, Rausch W D. Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate.  Brain Res. 2004;  1021 41-53
• 11 Hasegawa H, Sung J H, Matsumiya S, Uchiyama M, Inouye Y, Kasai R, Yamasaki K. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids.  Planta Med. 1995;  61 409-413
• 12 Choi C H, Kang G, Min Y D. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.  Planta Med. 2003;  69 235-240
• 13 Kim S W, Kwon H Y, Chi D W, Shim J H, Park J D, Lee Y H, Pyo S, Rhee D K. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3).  Biochem Pharmacol. 2003;  65 75-82
• 14 Kim H S, Lee E H, Ko S R, Choi K J, Park J H, Im D S. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells.  Arch Pharm Res. 2004;  27 429-435
• 15 Xie H T, Wang G J, Chen M, Jiang X L, Li H, Lv H, Huang C R, Wang R, Roberts M. Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells.  Biol Pharm Bull. 2005;  28 383-386
• 16 Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF‐CEM leukemia cells.  Blood Cells Mol Dis. 2002;  28 160-168
• 17 Jia W W, Bu X, Philips D, Yan H, Liu G, Chen X, Bush J A, Li G. Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy.  Can J Physiol Pharmacol. 2004;  82 431-437
• 18 Hasegawa H, Sung J H, Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins.  Planta Med. 1997;  63 436-440
• 19 Popovich D G, Kitts D D. Ginsenosides 20(S)-protopanaxadiol and Rh2 reduce cell proliferation and increase sub-G1 cells in two cultured intestinal cell lines, Int-407 and Caco-2.  Can J Physiol Pharmacol. 2004;  82 183-190
• 20 Liu G Y, Bu X, Yan H, Jia W W. 20S-Protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and ‐independent pathways.  J Nat Prod. 2007;  70 259-264
• 21 Yu Y, Zhou Q, Hang Y, Bu X, Jia W. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.  Cancer. 2007;  109 2374-2382
• 22 Aboudkhil S, Henry L, Zaid A, Bureau J P. Effect of testosterone on growth of P388 leukemia cell line in vivo and in vitro. Distribution of peripheral blood T lymphocytes and cell cycle progression.  Neoplasma. 2005;  52 260-266
• 23 Sharom F J, Liu R, Romsicki Y, Lu P. Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies.  Biochim Biophys Acta. 1999;  1461 327-345
• 24 Essodaigui M, Broxterman H J, Garnier-Suillerot A. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein.  Biochemistry. 1998;  37 2243-2250
• 25 Litman T, Zeuthen T, Skovsgaard T, Stein W D. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity.  Biochim Biophys Acta. 1997;  1361 169-176
• 26 Bruce C, Baguley D JK. Anticancer drug development. San Diego, CA, London; Academic 2002: 77-90